Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy
Anticoagulant therapy is recommended for cancer-related venous thromboembolism (VTE). Recurrent VTE prevention is the main goal of this treatment. The majority of evidence-based practice guidelines recommend anticoagulant treatment for at least 6 months. Based on individual assessment of potential...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
PAGEPress Publications
2024-05-01
|
| Saila: | Bleeding, Thrombosis and Vascular Biology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.btvb.org/btvb/article/view/124 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|